 CymaBay Therapeutics, Inc. CBAY, a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis PBC. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta PPARδ that has demonstrated anti-cholestatic and anti-inflammatory effects in clinical studies for PBC. The electronic presentation titled Effects on Pruritus and Sleep Disturbance in Patients with Primary Biliary Cholangitis PBC after 1 year of Treatment with Seladelpar, a Peroxisome Proliferator-Activated Receptor Delta Agonist: Results of an Open-Label Phase 2 Study, highlights the effect of seladelpar treatment over one year 1yr on key patient reported measures of pruritus itching and quality of life QoL. 